Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.

Response is also considering running trials of the weight management drug RDX-002 in combination with GLP-1RA therapies.

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Newron has randomised the first participants in its ENIGMA-TRS 1 Phase III programme of evenamide for treatment-resistant ...